Radius falters after a PhIII osteoporosis fail and a breast cancer disappointment, sending shares plummeting

Radius Health saw shares tank on Wednesday after reporting two Phase III study results, one for an osteoporosis patch treatment that failed and one for a breast cancer therapy showing lower efficacy results than expected.

The biotech is looking to develop a patch version of its injectable Tymlos drug for...

Click to view original post